Cerebral Vasculitis: Diagnosis and Current Treatment Recommendations

Barbara E. Ostrov, Todd F. Barron

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The vasculitides are a heterogeneous group of disorders that involve inflammation, necrosis and, ultimately, occlusion of blood vessels. They can have variable CNS involvement, with some, such as isolated angiitis of the CNS (IACNS) and Takayasu’s arteritis, predominantly or exclusively involving the CNS, while others only occasionally cause neurological complications. The latter syndromes include Wegener’s granulomatosis, systemic lupus erythematosus and disorders that mimic vasculitis such as the antiphospholipid antibody syndrome. The treatment of vasculitides is generally with variable doses of corticosteroids and immunosuppressants. Prednisone (oral) and methylprednisolone (usually intravenous) are the most commonly used corticosteroids. Cyclophosphamide is one of the most potent drugs available to treat severe, life-threatening vasculitis. It is given as an oral or intravenous single daily dose regimen or as intravenous pulse therapy. The folate antagonist methotrexate is a useful steroid-sparing agent, and is often added to a corticosteroid regimen. Azathioprine, chlorambucil and cyclosporin have also been used for the treatment of vasculitis, but experience with these agents is limited. Newer therapies with possible, but still unproven, efficacy are intravenous immunoglobulin and monoclonal antibodies. Although general treatment guidelines can be suggested, treatment should be individualised for each vasculitic syndrome.

Original languageEnglish (US)
Pages (from-to)115-125
Number of pages11
JournalCNS Drugs
Volume3
Issue number2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Central Nervous System Vasculitis
Vasculitis
Adrenal Cortex Hormones
Intravenous Immunoglobulins
Therapeutics
Chlorambucil
Takayasu Arteritis
Granulomatosis with Polyangiitis
Antiphospholipid Syndrome
Methylprednisolone
Azathioprine
Immunosuppressive Agents
Prednisone
Folic Acid
Methotrexate
Systemic Lupus Erythematosus
Cyclophosphamide
Cyclosporine
Blood Vessels
Necrosis

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Ostrov, Barbara E. ; Barron, Todd F. / Cerebral Vasculitis : Diagnosis and Current Treatment Recommendations. In: CNS Drugs. 1995 ; Vol. 3, No. 2. pp. 115-125.
@article{557aad35b55244499e07f62a1a4fd8a5,
title = "Cerebral Vasculitis: Diagnosis and Current Treatment Recommendations",
abstract = "The vasculitides are a heterogeneous group of disorders that involve inflammation, necrosis and, ultimately, occlusion of blood vessels. They can have variable CNS involvement, with some, such as isolated angiitis of the CNS (IACNS) and Takayasu’s arteritis, predominantly or exclusively involving the CNS, while others only occasionally cause neurological complications. The latter syndromes include Wegener’s granulomatosis, systemic lupus erythematosus and disorders that mimic vasculitis such as the antiphospholipid antibody syndrome. The treatment of vasculitides is generally with variable doses of corticosteroids and immunosuppressants. Prednisone (oral) and methylprednisolone (usually intravenous) are the most commonly used corticosteroids. Cyclophosphamide is one of the most potent drugs available to treat severe, life-threatening vasculitis. It is given as an oral or intravenous single daily dose regimen or as intravenous pulse therapy. The folate antagonist methotrexate is a useful steroid-sparing agent, and is often added to a corticosteroid regimen. Azathioprine, chlorambucil and cyclosporin have also been used for the treatment of vasculitis, but experience with these agents is limited. Newer therapies with possible, but still unproven, efficacy are intravenous immunoglobulin and monoclonal antibodies. Although general treatment guidelines can be suggested, treatment should be individualised for each vasculitic syndrome.",
author = "Ostrov, {Barbara E.} and Barron, {Todd F.}",
year = "1995",
month = "1",
day = "1",
doi = "10.2165/00023210-199503020-00004",
language = "English (US)",
volume = "3",
pages = "115--125",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "2",

}

Cerebral Vasculitis : Diagnosis and Current Treatment Recommendations. / Ostrov, Barbara E.; Barron, Todd F.

In: CNS Drugs, Vol. 3, No. 2, 01.01.1995, p. 115-125.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cerebral Vasculitis

T2 - Diagnosis and Current Treatment Recommendations

AU - Ostrov, Barbara E.

AU - Barron, Todd F.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The vasculitides are a heterogeneous group of disorders that involve inflammation, necrosis and, ultimately, occlusion of blood vessels. They can have variable CNS involvement, with some, such as isolated angiitis of the CNS (IACNS) and Takayasu’s arteritis, predominantly or exclusively involving the CNS, while others only occasionally cause neurological complications. The latter syndromes include Wegener’s granulomatosis, systemic lupus erythematosus and disorders that mimic vasculitis such as the antiphospholipid antibody syndrome. The treatment of vasculitides is generally with variable doses of corticosteroids and immunosuppressants. Prednisone (oral) and methylprednisolone (usually intravenous) are the most commonly used corticosteroids. Cyclophosphamide is one of the most potent drugs available to treat severe, life-threatening vasculitis. It is given as an oral or intravenous single daily dose regimen or as intravenous pulse therapy. The folate antagonist methotrexate is a useful steroid-sparing agent, and is often added to a corticosteroid regimen. Azathioprine, chlorambucil and cyclosporin have also been used for the treatment of vasculitis, but experience with these agents is limited. Newer therapies with possible, but still unproven, efficacy are intravenous immunoglobulin and monoclonal antibodies. Although general treatment guidelines can be suggested, treatment should be individualised for each vasculitic syndrome.

AB - The vasculitides are a heterogeneous group of disorders that involve inflammation, necrosis and, ultimately, occlusion of blood vessels. They can have variable CNS involvement, with some, such as isolated angiitis of the CNS (IACNS) and Takayasu’s arteritis, predominantly or exclusively involving the CNS, while others only occasionally cause neurological complications. The latter syndromes include Wegener’s granulomatosis, systemic lupus erythematosus and disorders that mimic vasculitis such as the antiphospholipid antibody syndrome. The treatment of vasculitides is generally with variable doses of corticosteroids and immunosuppressants. Prednisone (oral) and methylprednisolone (usually intravenous) are the most commonly used corticosteroids. Cyclophosphamide is one of the most potent drugs available to treat severe, life-threatening vasculitis. It is given as an oral or intravenous single daily dose regimen or as intravenous pulse therapy. The folate antagonist methotrexate is a useful steroid-sparing agent, and is often added to a corticosteroid regimen. Azathioprine, chlorambucil and cyclosporin have also been used for the treatment of vasculitis, but experience with these agents is limited. Newer therapies with possible, but still unproven, efficacy are intravenous immunoglobulin and monoclonal antibodies. Although general treatment guidelines can be suggested, treatment should be individualised for each vasculitic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0028812511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028812511&partnerID=8YFLogxK

U2 - 10.2165/00023210-199503020-00004

DO - 10.2165/00023210-199503020-00004

M3 - Article

AN - SCOPUS:0028812511

VL - 3

SP - 115

EP - 125

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 2

ER -